CD44 and cancer: To address the heterogeneity of cancer cells, anti-EGFR/CD44 dual-RNA aptamers were conjugated to solid lipid NPs functionalized with dexamethasone for DOX delivery to MDA-MB-468 cells, overexpressing EGFR and CD44 [257].